NYSE Arca · LCTX
Lineage Cell Therapeutics, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for LCTX: Nov 5, 2026
Lineage Cell Therapeutics, Inc. Common Stock is estimated to report earnings on 11/05/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.02. The reported EPS for the same quarter last year was $-0.13.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.02 | $0.00 | $-0.03 | 3 |
| Dec 2026 | $-0.02 | $0.00 | $-0.03 | 3 |
| Mar 2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
| Jun 2027 | $-0.03 | $-0.03 | $-0.03 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
The Motley Fool · Zacks · Fintel- The Motley Fool · Aug 13, 8:32 PM EDTLineage Cell Therapeutics (LCTX) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo
- Zacks · Aug 6, 5:40 PM EDTLineage Cell (LCTX) Reports Q2 Loss, Lags Revenue EstimatesLineage Cell (LCTX) delivered earnings and revenue surprises of 0.00% and -80.46%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · May 13, 10:19 PM EDTLineage Cell Therapeutics (LCTX) Price Target Increased by 14.58% to 5.61The average one-year price target for Lineage Cell Therapeutics (NYSEAM:LCTX) has been revised to $5.61 / share. This is an increase of 14.58% from the prior estimate of $4.90 dated April 25, 2026. The price target is an average of many targets provided by ana
- Zacks · May 12, 5:10 PM EDTLineage Cell (LCTX) Reports Q1 Loss, Lags Revenue EstimatesLineage Cell (LCTX) delivered earnings and revenue surprises of -50.00% and -46.53%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 11, 5:15 PM EDTHalozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue EstimatesHalozyme Therapeutics (HALO) delivered earnings and revenue surprises of +3.73% and +5.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · May 7, 5:55 PM EDTGuardant Health (GH) Reports Q1 Loss, Beats Revenue EstimatesGuardant Health (GH) delivered earnings and revenue surprises of +4.60% and +8.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Apr 28, 8:04 PM EDTCanaccord Genuity Initiates Coverage of Lineage Cell Therapeutics (LCTX) with Buy RecommendationFintel reports that on April 28, 2026, Canaccord Genuity initiated coverage of Lineage Cell Therapeutics (NYSEAM:LCTX) with a Buy recommendation. Analyst Price Forecast Suggests 213.85% Upside
- Fintel · Mar 27, 8:07 AM EDTLineage Cell Therapeutics (LCTX) Price Target Increased by 20.00% to 5.10The average one-year price target for Lineage Cell Therapeutics (NYSEAM:LCTX) has been revised to $5.10 / share. This is an increase of 20.00% from the prior estimate of $4.25 dated February 21, 2026. The price target is an average of many targets provided by
- Zacks · Mar 5, 5:30 PM ESTLineage Cell (LCTX) Reports Break-Even Earnings for Q4Lineage Cell (LCTX) delivered earnings and revenue surprises of +100.00% and +187.81%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Mar 3, 9:15 AM ESTPrime Medicine, Inc. (PRME) Reports Q4 Loss, Misses Revenue EstimatesPrime Medicine, Inc. (PRME) delivered earnings and revenue surprises of +13.39% and -63.64%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Feb 26, 5:30 PM ESTPacira (PCRX) Lags Q4 Earnings and Revenue EstimatesPacira (PCRX) delivered earnings and revenue surprises of -32.74% and -0.06%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
- Fintel · Nov 25, 10:33 AM ESTD. Boral Capital Maintains Lineage Cell Therapeutics (LCTX) Buy RecommendationFintel reports that on November 25, 2025, D. Boral Capital maintained coverage of Lineage Cell Therapeutics (NYSEAM:LCTX) with a Buy recommendation. Analyst Price Forecast Suggests 142.86% Upside
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Lineage Cell Therapeutics, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.